Antibodies with High Avidity to the gp120 Envelope Protein in Protection from Simian Immunodeficiency Virus SIV(mac251) Acquisition in an Immunization Regimen That Mimics the RV-144 Thai Trial

The recombinant canarypox vector, ALVAC-HIV, together with human immunodeficiency virus (HIV) gp120 envelope glycoprotein, has protected 31.2% of Thai individuals from HIV acquisition in the RV144 HIV vaccine trial. This outcome was unexpected, given the limited ability of the vaccine components to...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Pegu, Poonam, Vaccari, Monica, Gordon, Shari, Keele, Brandon F., Doster, Melvin, Guan, Yongjun, Ferrari, Guido, Pal, Ranajit, Ferrari, Maria Grazia, Whitney, Stephen, Hudacik, Lauren, Billings, Erik, Rao, Mangala, Montefiori, David, Tomaras, Georgia, Alam, S. Munir, Fenizia, Claudio, Lifson, Jeffrey D., Stablein, Donald, Tartaglia, Jim, Michael, Nelson, Kim, Jerome, Venzon, David, Franchini, Genoveffa
Format: Artigo
Jezik:Inglês
Izdano: American Society for Microbiology 2013
Teme:
Vaccines and Antiviral Agents
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3554145/
https://ncbi.nlm.nih.gov/pubmed/23175374
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.02544-12
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items